

Andrea Alimonti, MD
Curriculum Vitae

General Information

Date prepared: 5/01/2015

Name: Andrea Alimonti

Date of birth: 07/09/1975

Actual Position: **Head, Molecular Oncology**
Institute of Oncology Research
Oncology Institute of Southern Switzerland
Bellinzona, Switzerland.

Education:

2000	MD degree, Magna Cum Laude (GPA: 110/110) University of Rome “La Sapienza” Rome, Italy
2004	Residency in Clinical Oncology, Magna Cum Laude Regina Elena National Cancer Institute , Rome, Italy
2013	PD, University of Lausanne (UNIL), Faculty of Biology and Medicine Lausanne, Switzerland
2013	Associated Professor Habilitation in Oncology and Molecular Biology- Italian National Scientific Qualification (ANVUR 06/D3; 05/E2)

Postdoctoral Training:

2007– 2009	BIDMC-Harvard Medical School Boston, United States Division of Cancer Genetics, Lab.: Pier Paolo Pandolfi MD Phd. Position: Postdoctoral Clinical/Research Fellow
2004–2007	Memorial Sloan-Kettering Cancer Center New York, United States Division of Human Pathology, Lab.: Pier Paolo Pandolfi MD Phd. Position: Postdoctoral Clinical/Research Fellow
2000–2004	Regina Elena National Cancer Institute of Rome Rome, Italy Division of Medical Oncology: Prof. Francesco Cognetti Position: Resident in Clinical Oncology

Fellowships, Grants and Awards:

2015	J. Steiner Cancer Research Award
2010-2015	European Research Council (ERC) starting Grant
2011- 2015	Ambizione-SCORE grant (FNSNF)
2010- 2013	Swiss Bridge Award
2009-2010	European Society of Medical Oncology (ESMO) Award in Translational Research.
2008- 2012	Marie Curie International Reintegration Grant (IRG)
2004 - 2005	Susan Komen Breast Cancer Foundation (Komen Italia)
2003 - 2004	Italian Association of Clinical Oncology (AIOM)

Scientific and Medical Societies:

Member of the Young Academy of Europe
 Full Member of the European Society of Medical Oncology (ESMO)
 Full Member of the American Association for Cancer Research (AACR)
 Member of the urogenital cancer board of SAKK

Editorial Boards:

Ad hoc reviewer for the Journal of Clinical Oncology (JCO), Clinical Cancer Research, European Journal of Cancer and Cancer Chemotherapy and Pharmacology, PNAS

Languages Italian; English; Spanish

Part II:**A. Founding Information**

2015-2019	J. Steiner Foundation (1M CHF)
2015-2018	Horten Foundation (250 K CHF)
2015-2018	Krebsliga (300K CHF)
2011- 2015	Ambizione-SCORE grant (FNSNF) (500K CHF)
2010-2016	European Research Council (ERC) starting Grant (1.5 M Euro)
2012-2016	IIR Pfizer Grant (150K USD)
2012-2013	Novartis Foundation (50K CHF)
2010-2013	Swiss Bridge Award (250K CHF)
2009-2010	European Society of Medical Oncology (ESMO) Research Grant (50K Euro)
2008-2012	Marie Curie International Reintegration Grant (150K Euro)
2007 -2008	Department of Cancer Genetics, BIDMC Harvard Medical School, “Co-clinical trial project”
2006-2007	Department of Medicine, Prostate Cancer Division, “MSKCC fellowship and career support”
2005-2006	Susan G. Komen foundation fellowship
2004-2005	Italian Association of Medical Oncologist (AIOM) fellowship

B. Regional, National, and international Contribution**Invited Lectures:****2015 IBSA Workshop in Cancer and Immunology, Switzerland (organizer)**

Alimonti A: Immune senescence therapy for Cancer

2015 ICSA meeting, Santiago de Compostela (scheduled)

Alimonti A: Pten loss induced cellular senescence

2015, AIMAR, Pescara Italia (scheduled)

Alimonti A: Role of myeloid cells in chemotherapy resistance (Scheduled)

2015, AFI (Farindustria) meeting, Rimini, Italia (Scheduled)

Alimonti A: Immunotherapy in prostate cancer

2015, Edinburgh Cancer Research Centre(scheduled)

Alimonti A: Immune senescence therapy for cancer

2015, MRC, London (scheduled)

Alimonti A: Targeting senescence for cancer therapy

2015.EMBO meeting, Europhosphatase 2015 (scheduled)

Alimonti A: Identification of a novel phosphatase network that promotes tumor immune evasion

2015. IDIBELL, Barcellona (scheduled)

Targeting senescence for cancer therapy

2014. Novartis, Basel meeting

Immune senescence therapy for Cancer

2014 University of Padova”, Italy

Pro-senescence therapy for Cancer

2014. EMBO meeting, Translational advances in cancer cell signaling and metabolism, Bilbao, Spain.

Alimonti A: Targeting the tumor immune system for pro-senescence therapy for cancer

2014 1th ESMO Symposium on Signaling Pathways

Alimonti A: PTEN

2013 Cologne University Hospital “Onco-seminar series”

Alimonti A: “Pro-senescence” therapy for cancer

2013 Sino Swiss Symposium, Beijing, China

Alimonti A: Reprogramming the senescence associated tumor secretory phenotype for cancer therapy

2013 Barts and the London School of Medicine

Alimonti A: Reprogramming the senescence associated tumor secretory phenotype for cancer therapy

2013 Centre Hospitalier Universitaire Vaudois Lausanne, Switzerland

Alimonti A: Immune-senescence therapy for cancer

2013 UNIRAD meeting, Paris, France

Alimonti A: Targeting mTOR for cancer therapy

2012 Cibiogune, Bilbao, Spain

Alimonti A: Immune-senescence therapy for cancer

2012 Stepping Stone Symposium, ETH Zurich, Switzerland

Alimonti A: PTEN levels in tumor suppression and cancer therapy

2012 4th IMPAKT Breast Cancer Conference, Brussels, Belgium

Alimonti A: PTEN loss a master regulator?

2011 TAT 2011 International Symposium on targeted anticancer therapies, Paris, France

Alimonti A: PTEN loss induced cellular senescence for “Pro-senescence” therapy for cancer.

Bibliography:

Original Reports

1. Madhuri Kalathur, Alberto Toso, Jingjing Chen, Ajinkya Revandkar, Claudia Danzer-Baltzer, Iliaria Guccini, Abdullah Alajati, Manuela Sarti, Sandra Pinton, Lara Brambilla, Diletta Dimitri, Giuseppina Carbone, Ramon Garcia-Escudero, Alessandro Padova, Letizia Magnoni, Dr. Laura Maccari, Mr. Federico Malusa, Dr. Ravi Kiran Kalathur, Prof. Lorenzo Pinna, Maria Ruzzene, Giorgio Cozza, Carlo Catapano, Ian Frew & Andrea Alimonti. A combined chemogenomic and shRNA-screening platform identifies CK2 as a novel target for pro-senescence therapy in PTEN null tumors. *Nature Communications* (second revision)
2. Alberto Toso, Diletta Di Mitri & Andrea Alimonti. Enhancing chemotherapy efficacy by reprogramming the senescence-associated secretory phenotype of prostate tumors. "A way to reactivate the anti-tumor immunity". ***Oncoimmunology* 2015** (accepted)
3. Diletta Di Mitri, Alberto Toso & Andrea Alimonti. Tumour infiltrating myeloid cells drive senescence evasion and chemoresistance in cancer. ***Oncoimmunology* 2015** (accepted)
4. Diletta Di Mitri, Alberto Toso, Jing Jing Chen, Manuela Sarti, Sandra Pinton, Tanja Rezzonico Jost, Rocco D'Antuono, Erica Montani, Ramon Garcia-Escudero, Iliaria Guccini, Sabela Da Silva, Manuel Collado, Mario Eisenberger, Zhe Zheng, Carlo Catapano, Fabio Grassi & Andrea Alimonti. Tumour infiltrating Gr-1+ myeloid cells antagonize senescence in cancer. ***Nature* 2014** Aug 24. doi: 10.1038/nature13638.
5. Alberto Toso, Ajinkya Revandkar, Diletta Di Mitri, Iliaria Guccini, Michele Proietti, Manuela Sarti, Sandra Pinton, Jiangwen Zhang, Madhuri Kalathur, Gianluca Civenni, David Jarrossay, Camilla Marini, Eugenio Scanziani, Fabio Grassi, Pier Paolo Pandolfi, Carlo V. Catapano and Andrea Alimonti. Reactivation of senescence surveillance in Pten loss induced cellular senescence ***Cell Reports* 9**, 1–15, October 9, 2014
6. Nardella C, Clohessy JG, **Alimonti A**, Panodlfi PP. Pro-senescence therapy for cancer treatment. ***Nat Rev Cancer***. 2011 Jun 24;11(7):503-11
7. Carracedo A, **Alimonti A**, Pandolfi PP. PTEN level in tumor suppression: how much is too little? *Cancer Res* 2011 Feb 1;71(3):629-33
8. Nardella C, Lunardi A, Fedele G, Clohessy JG, **Alimonti A**, Kozma SC, Thomas G, Loda M, Pandolfi PP. Differential expression of S6K2 dictates tissue-specific requirement for S6K1 in mediating aberrant mTORC1 signaling and tumorigenesis. *Cancer Res*. 2011 May 15;71(10):3669-75
9. **A. Alimonti**, A. Carracedo, J. G. Clohessy, C. Nardella, L. C. Trotman, C. Nardella, A. Egia, L. Salmena, K. Sampieri, E. Brogi, J. Zhang, A. Richardson and P. P. Pandolfi. Subtle variations in Pten dose determine breast cancer susceptibility. ***Nat Genet***. 2010 May;42(5):454-8.
10. **A. Alimonti**, C. Nardella, Z. Chen, J. G. Clohessy, L. C. Trotman, A. Carracedo, K. Cheng, S. Varmeh-Ziaie, M. B. Kastan, S.C. Kozma, G. Thomas, E. Rosivatz, R. Woscholski, F.Cognetti, H.I. Scher and P. P. Pandolfi. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. ***J Clin Invest***. 2010 Mar;120(3):681-93
11. **Alimonti A**. PTEN breast cancer susceptibility: a matter of dose *Ecancermedicalscience*. 010;4:192.
12. I. Pavese, F. Satta, P.Piergrossi, E. Brunetti & **A. Alimonti**. High serum levels of TNF-alpha and IL-6 predict the clinical outcome of treatment with human recombinant erythropoietin in anaemic cancer patients. *Ann Oncol*. 2009 Dec 23.

13. Chen Z, Carracedo A, Lin HK, Koutcher JA, Behrendt N, Egia A, **Alimonti A**, Carver BS, Gerald W, Teruya-Feldstein J, Loda M, Pandolfi PP. Differential p53-independent outcomes of p19(Arf) loss in oncogenesis *Sci Signal*. 2009 Aug 18;2(84):ra44.
14. Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, **Alimonti A**, Nardella C, Varmeh S, Scardino PT, Cordon-Cardo C, Gerald W, Pandolfi PP. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. ***Nat Genet***. 2009 May;41(5):619-24. Epub 2009 Apr 26.
15. Carver BS, Tran J, Chen Z, Carracedo-Perez A, **Alimonti A**, Nardella C, Gopalan A, Scardino PT, Cordon-Cardo C, Gerald W, Pandolfi PP. ETS rearrangements and prostate cancer initiation. ***Nature***. 2009 Feb 12;457(7231):E1; discussion E2-3.
16. Nardella C, Carracedo A, **Alimonti A**, Hobbs RM, Clohessy JG, Chen Z, Egia A, Fornari A, Fiorentino M, Loda M, Kozma SC, Thomas G, Cordon-Cardo C, Pandolfi PP. Differential requirement of mTOR in postmitotic tissues and tumorigenesis. ***Sci Signal***. 2009 Jan 27;2(55):ra2
17. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, **Alimonti A**, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. ***J Clin Invest***. 2008 Sep;118(9):3065-74
18. Nardella C, Chen Z, Salmena L, Carracedo A, **Alimonti A**, Egia A, Carver B, Gerald W, Cordon-Cardo C, Pandolfi PP. Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. ***Genes Dev***. 2008 Aug 15;22(16):2172-7
19. X. Wang, L. Trotman, T. Koppie, **A. Alimonti**, Z. Gao, J. Wang, H. Erdjument-Bromage, P. Tempst, C. Cordon-Cardo, P.P. Pandolfi and X. Jiang. NEDD 4-1 is the Proto-oncogenic Ubiquitin ligase for PTEN. ***Cell***. 2007 Jan 12;128(1):129-39.
20. L.C. Trotman, X. Wang, **A. Alimonti**, Z. Chen, J. Teruya-Feldstein, S-G. Chi, H-J. Kim, H. Yang, N.P. Pavletich, B.S. Carver, H. Erdjument-Bromage, P. Tempst, C. Cordon-Cardo, T. Misteli. X. Jiang and P.P. Pandolfi. Ubiquitination regulates nuclear PTEN import and tumor suppression as revealed by inherited mutation. ***Cell***. 2007 Jan 12; 128(1): 141-56.
21. L.C. Trotman, **A. Alimonti**, P.P. Scaglioni, J.A. Koutcher, C. Cordon-Cardo and P.P. Pandolfi. Identification of a tumour suppressor network opposing nuclear Akt function. ***Nature***, 441:523-7 2006
22. Bernardi R, Guernah I, Jin D, Grisendi S, **Alimonti A**, Teruya-Feldstein J, Cordon-Cardo C, Simon MC, Rafii S, Pandolfi PP. PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. ***Nature***. 2006 Aug 17; 442(7104):779-8
23. Ferretti G, **Alimonti A**, Cognetti F. Is thymidylate synthase a reliable predictor for response and survival during hepatic arterial infusion for hepatic metastases from colorectal cancer? *Br J Cancer*. 2006 Nov 6;95(9):1304-5; author reply 1306-7. Epub 2006 Oct 17
24. Migliore A, Tormenta S, Massafra U, Carloni E, Padalino C, Iannessi F, **Alimonti A**, Martin LS, Granata M. Repeated ultrasound-guided intra-articular injections of 40 mg of Hyalgan may be useful in symptomatic relief of hip osteoarthritis. *Osteoarthritis Cartilage*. 2005 Dec;13(12):1126-7. Epub 2005 Oct 19.
25. Migliore A, Tormenta S, Martin Martin LS, Iannessi F, Massafra U, Carloni E, Monno D, **Alimonti A**, Granata M. The symptomatic effects of intra-articular administration of hylan G-F 20 on osteoarthritis of the hip: clinical data of 6 months follow-up. *Clin Rheumatol*. 2006 May;25(3):389-93. Epub 2005 Oct 25
26. **Alimonti A**, Ferretti G, Cognetti F. Can the reliance of hormone receptor assays of surgical specimens be explained by the fluctuation of estrogen receptor, progesterone receptor, and

- HER-2 protein expression in tumor samples of premenopausal breast cancer patients? **J Clin Oncol.** 2005 Dec 1;23(34):8918
27. Migliore A, Massafra U, Carloni E, Padalino C, Martin Martin S, Lasaracina F, Dibiasi N, **Alimonti A**, Granata M. TNF-alpha blockade induce clinical remission in patients affected by polymyalgia rheumatica associated to diabetes mellitus and/or osteoporosis: a seven cases report. *Eur Rev Med Pharmacol Sci.* 2005 Nov-Dec; 9(6):373-8.
 28. Ferretti G, Fabi A, Carlini P, Papaldo P, Cordiali Fei P, Di Cosimo S, Salesi N, Giannarelli D, **Alimonti A**, Di Cocco B, D'Agosto G, Bordignon V, Trento E, Cognetti F. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. *Oncology.* 2005; 69(1): 35-43. Epub 2005 Aug 2.
 29. **Alimonti A**, Nardoni C, Papaldo P, Ferretti G, Caleno MP, Carlini P, Fabi A, Rasio D, Vecchione A, Cognetti F. Nail disorders in a woman treated with ixabepilone for metastatic breast cancer. *Anticancer Res.* 2005 Sep-Oct;25(5):3531-2
 30. Di Cosimo S, Ferretti G, Papaldo P, Carlini P, Fabi A, Ruggeri EM, **Alimonti A**, Nardoni C, Cognetti F. Does the concurrent use of anthracycline and granulocyte colony-stimulating factor influence the risk of secondary leukaemia in breast cancer women? *Ann Oncol.* 2005 Jul;16(7):1209-10. Epub 2005 Apr 27.
 31. Migliore A, Tormenta S, Valente C, Massafra U, Martin Martin LS, Carmenini E, Bernardini A, **Alimonti A**. Intra-articular treatment with Hylan G-F 20 under ultrasound guidance in hip osteoarthritis. Clinical results after 12 months follow-up. *Reumatismo.* 2005 Jan-Mar;57(1):36-43.
 32. **Andrea Alimonti**, Alain Gelibter, Ida Pavese, Francesco Satta, Gianluigi Ferretti, Francesco Cognetti, and Mario Di Palma. New approaches to prevent the intestinal toxicity of irinotecan-based regimens. *Cancer Treat Rev.* 2004 Oct; 30(6):555-62. Review.
 33. **Alimonti A**, Di Cosimo S, Ferretti G, Sperduti I, Carlini P, Papaldo P, Fabi A, Gelibter A, Ciccarese M, Giannarelli D, Mandala M, Milella M, Ruggeri EM, Cognetti F. Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer. *Ann Oncol.* 2004 Jul;15(7):1065-71
 34. Migliore A, Tormenta S, Martin LS, Valente C, Massafra U, Granata M, **Alimonti A**. Open pilot study of ultrasound-guided intra-articular injection of hylan G-F 20 (Synvisc) in the treatment of symptomatic hip osteoarthritis. *Clin Rheumatol.* 2005 Jun;24(3):285-9. Epub 2004 Dec 9.
 35. Ferretti G, Di Cosimo S, Giannarelli D, Papaldo P, **Alimonti A**, et al. Endocrine adjuvant therapy and Her-2 neu over-expression: Can muddy water become clear ? *JCO* 2004 February
 36. Migliore A, Tormenta S, Martin Martin LS, Valente C, Massafra U, Latini A, **Alimonti A**. Safety profile of 185 ultrasound-guided intra-articular injections for treatment of rheumatic diseases of the hip. *Reumatismo.* 2004 Apr-Jun;56(2):104-9.
 37. **Alimonti A**, Di Cosimo S, Di Palma M, Ferretti G, Vecchione A. Is video-assisted thoracic surgery always safe? *Minerva Chir.* 2004 Aug;59(4):413-4
 38. **Alimonti A**. et al. May colorectal cancer patients with Thymidylate-Sintetase positive liver metastases have an overall survival advantage by hepatic arterial infusion alone? *J Clin Oncol.* 2003 Sep 15;21(18):3543-4
 39. **Alimonti A**. et al "A woman with subacute motor weakness and left renal mass". *Am J Med.* 2003 Jun 1;114(8):706-8
 40. **Alimonti A**. et al. A man with a deltoid mass and erythrocytosis: case report and review of the cases. *Anticancer Res.* 2003 Nov-Dec; 23(6D):5181-4.

41. Martin-Martin LS, Latini A, Pagano A, Ragno A, Stasi R, Coppe A, Davoli G, Crescenzi A, **Alimonti A**, Migliore A. A new mathematical model based on clinical and laboratory variables for the diagnosis of Sjogren's syndrome. *Clin Rheumatol*. 2003 May;22(2):123-124
42. **Alimonti A** et al. Prevention of irinotecan plus 5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer. *Ann. Oncol* 2003 14: 805-a-806-a
43. Migliore A, Martin LS, **Alimonti A**, Valente C, Tormenta S. Efficacy and safety of viscosupplementation by ultrasound-guided intra-articular injection in osteoarthritis of the hip. *Osteoarthritis Cartilage*. 2003 Apr;11(4):305-6
44. Di Cosimo S, i Ferretti G, Fazio N, Silvestris N, Carlini P, Alimonti A, et al. Docetaxel in Advanced Gastric Cancer. *Acta Oncologica* Volume 42, Number 7 / November 2003.

Monographs

1. Madhuri Kalathur, Diletta Di Mitri, **Andrea Alimonti**. Pro-senescence therapy for cancer: time for the clinic. 'Stress Response Pathways in Cancer: From Molecular Targets to Novel Therapeutics' to be published by Springer Science
2. **Alimonti A**, Monorchio A, Quirino N, Alimonti P. Ambiente, inquinamento da autoveicoli e patologie respiratorie: costi sanitari, socio-economici e possibili soluzioni. An Ageing Society dossier. Ageing and Health study Group